Algert Global LLC Has $1.92 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Algert Global LLC trimmed its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 37.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,848 shares of the company's stock after selling 14,369 shares during the quarter. Algert Global LLC's holdings in PROCEPT BioRobotics were worth $1,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in PRCT. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Thematics Asset Management bought a new stake in PROCEPT BioRobotics in the fourth quarter worth $46,000. Signaturefd LLC boosted its holdings in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new position in PROCEPT BioRobotics during the fourth quarter worth $58,000. Finally, Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics during the fourth quarter valued at about $64,000. Institutional investors own 89.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PRCT. Bank of America lowered their price objective on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Truist Financial decreased their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $90.00.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock traded down $1.69 during mid-day trading on Friday, reaching $53.12. The company had a trading volume of 470,506 shares, compared to its average volume of 805,692. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a 50 day moving average of $55.66 and a 200-day moving average of $72.90. PROCEPT BioRobotics Co. has a 52 week low of $47.04 and a 52 week high of $103.81. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -27.24 and a beta of 1.10.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. PROCEPT BioRobotics's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) earnings per share. On average, sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 over the last quarter. Company insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).